NCT02398773 2026-03-18
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT07112053 2026-03-09
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT05659797 2026-02-27
FES BPET-DBT in Newly Diagnosed Breast Cancer
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Recruiting
NCT04692103 2026-01-22
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
University of Washington
Phase 2 Active not recruiting
NCT06260033 2025-10-06
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT02409316 2025-08-08
[18F]FES PET/CT in Endocrine Refractory Breast Cancer
University of Pennsylvania
Phase 2 Completed
NCT05916196 2025-05-08
[18F]FES PET/.CT in Uterine Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT03703492 2025-02-12
Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS
University of Wisconsin, Madison
Phase 2 Completed
NCT02149173 2021-06-30
F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy
University of Washington
Phase NA Terminated